Product Description
Mechanisms of Action: ADORA1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Rocket Pharmaceuticals
Company Location: NEW YORK NY 10118
Company CEO: Gaurav Shah
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Glaucoma, Open-Angle|Hypertension
Phase 2: Hypertension|Glaucoma, Open-Angle
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IPC-02-2015 | P2 |
Completed |
Glaucoma, Open-Angle|Hypertension |
2017-05-24 |
|
| MATrX-1 | P3 |
Completed |
Hypertension|Glaucoma, Open-Angle |
2016-11-01 |
|
| IPC-01-2013 | P2 |
Completed |
Glaucoma, Open-Angle|Hypertension |
2014-08-01 |
|
| IPC-10-2009 | P2 |
Completed |
Glaucoma, Open-Angle|Hypertension |
2011-12-01 |